Abstract
Non-Hodgkin lymphomas (NHL) account for 7% of childhood malignancies between the ages of 0 and 19 according to SEERS data from 2010 to 2014. NHL are rare in early childhood with an incidence of 7.3/106 children/year in the 1–4-year age group. By adolescence, the annual incidence rises with 14/106 children in the 10–14-year age range and 18.3/106 children in the 15–19-year age group. In addition, lymphoblastic leukemia accounts for another 20% of childhood cancers making malignancies of lymphatic origin the largest group of childhood cancers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Reiter A. Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2007;2007:285–96.
Burkhardt B, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49.
Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents—review of standard chemotherapy regimen and perspectives. Pediatr Hematol Oncol. 2013;30(6):465–83.
Lange J, Burkhardt B. Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. Curr Hematol Malig Rep. 2013;8(3):226–35.
Sandlund JT, Downing JR, Crist WM. Non-Hodgkin’s lymphoma in childhood. N Engl J Med. 1996;334(19):1238–48.
Burkhardt B, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011;25(1):153–60.
Salzburg J, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Munster Group report. J Clin Oncol. 2007;25(25):3915–22.
Cairo MS, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (>/= 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387–93.
Abla O, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res. 2011;17(2):346–52.
Thorer H, et al. Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to Non-Hodgkin-Lymphoma Berlin-Frankfurt-Munster protocols for systemic lymphoma. Haematologica. 2014;99(11):e238–41.
Swerdlow SH, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissue. World Health Organization classification of tumours. Lyon: IARC; 2008.
Swerdlow SH, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909–18.
Hummel M, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–30.
Dave SS, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–42.
Mbulaiteye SM, et al. Pediatric, elderly, and emerging adult-onset peaks in Burkitt’s lymphoma incidence diagnosed in four continents, excluding Africa. Am J Hematol. 2012;87(6):573–8.
Boerma EG, et al. Gender and age-related differences in Burkitt lymphoma—epidemiological and clinical data from The Netherlands. Eur J Cancer. 2004;40(18):2781–7.
Molyneux EM, et al. Burkitt’s lymphoma. Lancet. 2012;379(9822):1234–44.
Schmitz R, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–20.
Richter J, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44(12):1316–20.
Love C, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44(12):1321–5.
Campo E. New pathogenic mechanisms in Burkitt lymphoma. Nat Genet. 2012;44(12):1288–9.
Rohde M, et al. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Munster protocols. Haematologica. 2017;102(6):1091–8.
Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(Suppl 3):S41–7.
Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.
Rosenwald A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.
Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.
Choi WW, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009;15(17):5494–502.
Oschlies I, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006;107(10):4047–52.
Szczepanowski M, et al. Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents. Br J Haematol. 2017;179(1):116–9.
Salaverria I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139–47.
Miles RR, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008;51(3):369–74.
Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–9.
Rosolen A, et al. Revised international pediatric non-Hodgkin lymphoma staging system. J Clin Oncol. 2015;33(18):2112–8.
Woessmann W, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948–58.
Reiter A, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–306.
Fujita N, et al. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma. 2011;52(2):223–9.
Patte C, et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–9.
Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80.
Cairo MS, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–43.
Pillon M, et al. Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). Cancer. 2004;101(2):385–94.
A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94.
Gerrard M, et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008;141(6):840–7.
Kikuchi A, et al. Outcome of childhood B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia treated with the Tokyo Children’s Cancer Study Group NHL B9604 protocol. Leuk Lymphoma. 2008;49(4):757–62.
Jourdain A, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Societe Francaise des Cancers de l’Enfant study. Haematologica. 2015;100(6):810–7.
Anoop P, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(10):1882–8.
Gross TG, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223–30.
Fujita N, et al. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer. 2008;51(2):188–92.
Woessmann W, Reiter A. Re-induction approaches to relapsed/refractory childhood and adolescent non Hodgkin¢s lymphoma: BFM perspective. Br J Haematol. 2012;159(Suppl. 1):Abstract 71.
Griffin TC, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;52(2):177–81.
Samochatova EV, et al. Therapy of advanced-stage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol. 2014;36(5):395–401.
Meinhardt A, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28(19):3115–21.
Lisfeld J, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia: dose-escalation does not increase the response rate. Br J Haematol. 2012;112(Suppl. 2012):Abstract 6.
Cairo M, et al. Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: a Children’s Oncology Group report. JCO. 2010;28(15s):9536.
Frazer K, et al. Efficacy of rituximab plus FAB group C chemotherapy without CNS radiation in CNS-positive pediatric Burkitt lymphoma/leukemia: a report from the Children’s Oncology Group. JCO. 2012;30(15_suppl):9501.
Goldman S, et al. Preliminary results of the addition of Rasburicase to the reduction cycle and rituximab to the induction and consolidation cycles of FAB Group C Chemotherapy in Children and Adolescents with Advanced Stage (Bone Marrow ±CNS) Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): a Children’s Oncology Group report. Blood. 2009;114:104.
Goldman S, et al. The efficacy of rasburicase and rituximab combined with FAB chemotherapy in children and adolescents with newly diagnosed stage III/IV, BM+ and CNS+ Mature B-NHL: a Children’s Oncology Group Report. Blood. 2011;118:2702.
Goldman S, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167(3):394–401.
Goldman S, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia. 2013;27(5):1174–7.
Barth MJ, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children’s Oncology Group report. Br J Haematol. 2013;162(5):678–83.
Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel). 2015;7(1):305–28.
Schmidt E, Burkhardt B. Lymphoblastic lymphoma in childhood and adolescence. Pediatr Hematol Oncol. 2013;30(6):484–508.
Oschlies I, et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2011;96(2):262–8.
Ducassou S, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol. 2011;152(4):441–51.
Neth O, et al. Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol. 2000;35(1):20–7.
Bene MC, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–6.
Oschlies I, et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol. 2011;35(6):836–44.
Patel JL, et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children’s Oncology Group report. Br J Haematol. 2012;159(4):454–61.
Smock KJ, et al. Characterization of childhood precursor T-lymphoblastic lymphoma by immunophenotyping and fluorescent in situ hybridization: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2008;51(4):489–94.
Coustan-Smith E, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147–56.
You MJ, Medeiros LJ, Hsi ED. T-lymphoblastic leukemia/lymphoma. Am J Clin Pathol. 2015;144(3):411–22.
Haydu JE, Ferrando AA. Early T-cell precursor acute lymphoblastic leukaemia. Curr Opin Hematol. 2013;20(4):369–73.
Patrick K, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2014;166(3):421–4.
Burkhardt B, et al. Current status and future directions of T-lymphoblastic lymphoma in children and adolescents. Br J Haematol. 2016;173(4):545–59.
Tubergen DG, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin’s lymphoma: a Childrens Cancer Group study. J Clin Oncol. 1995;13(6):1368–76.
Abromowitch M, et al. High-dose methotrexate and early intensification of therapy do not improve 3 year EFS in children and adolescents with disseminated lymphoblastic lymphoma. Results of the randomized arms of COG A5971. Blood. 2008;112:3610.
Uyttebroeck A, et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer. 2008;44(6):840–6.
Reiter A, et al. Results of the European intergroup trial EURO-LB02 on lymphoblastic lymphoma (LBL) in children/adolescents. Br J Haematol. 2012;159(Suppl. 1):38.
Burkhardt B. Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? Br J Haematol. 2010;149(5):653–68.
Basso K, et al. T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses. Genes Chromosomes Cancer. 2011;50(12):1063–75.
Uyttebroeck A, et al. Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma? Leuk Lymphoma. 2007;48(9):1745–54.
Burkhardt B, et al. Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia. 2006;20(8):1422–9.
Lones MA, et al. Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. Cancer Genet Cytogenet. 2007;172(1):1–11.
Breit S, et al. Activating NOTCH1 mutations predict favorable early treatment response and long term outcome in child-hood precursor T-cell lymphoblastic leukemia. Blood. 2006;108(4):1151–7.
Kox C, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia. 2010;24(12):2005–13.
Bonn BR, et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood. 2013;121(16):3153–60.
Callens C, et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol. 2012;30(16):1966–73.
Park MJ, et al. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol. 2009;145(2):198–206.
Baleydier F, et al. T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res. 2008;14(3):692–700.
Burkhardt B, et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma. 2008;49(3):451–61.
Balbach ST, et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia. 2016;30(4):970–3.
Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96.
Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of gamma-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal. 2014;26(1):149–61.
Bandapalli OR, et al. NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica. 2013;98(6):928–36.
Zuurbier L, et al. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia. 2010;24(12):2014–22.
Gutierrez A, et al. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3816–23.
Yang YL, et al. Absence of biallelic TCRgamma deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;58(6):846–51.
Stark B, et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer. 2009;52(1):20–5.
Coustan-Smith E, et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the Children’s Oncology Group. J Clin Oncol. 2009;27(21):3533–9.
Mussolin L, et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: the AIEOP experience. Pediatr Blood Cancer. 2015;62(11):1906–13.
Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 2002;21(35):5427–40.
Roman-Gomez J, et al. Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma. 2007;48(7):1269–82.
Bardi E, et al. Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas. Pathol Oncol Res. 2014;20(1):139–43.
Nakatani K, et al. Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma. Clin Nucl Med. 2012;37(7):656–62.
Riad R, et al. Role of PET/CT in malignant pediatric lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(2):319–29.
Riad R, et al. False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt’s lymphoma. Nucl Med Commun. 2010;31(3):232–8.
Sioka C. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Eur J Pediatr. 2013;172(6):733–8.
Patte C, et al. Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr Oncol. 1992;20(2):105–13.
Amylon MD, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13(3):335–42.
Reiter A, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000;95(2):416–21.
Burkhardt B, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006;24(3):491–9.
Abromowitch M, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology Group. Br J Haematol. 2008;143(2):261–7.
Pillon M, et al. Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of pediatric hematology and oncology. Pediatr Blood Cancer. 2009;53(6):953–9.
Sandlund JT, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia. 2009;23(6):1127–30.
Asselin BL, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874–83.
Termuhlen AM, et al. Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children’s Oncology Group trial A5971: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59(7):1229–33.
Uyttebroeck A, et al. Dexamethasone (DEX) versus prednisone (PRED) in T-cell non Hodgkin lymphoma (T-NHL): results of the randomized phase III trial 58951 of the EORTC Children Leukemia Group. Br J Haematol. 2012;159(Suppl. 1):37.
Bergeron C, et al. Treatment of childhood T-cell lymphoblastic lymphoma-long-term results of the SFOP LMT96 trial. Pediatr Blood Cancer. 2015;62(12):2150–6.
Wollner N, et al. Non-Hodgkin’s lymphoma in children. A comparative study of two modalities of therapy. Cancer. 1976;37(1):123–34.
Wollner N, Exelby PR, Lieberman PH. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979;44(6):1990–9.
Reiter A, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage—a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13(2):359–72.
Jin L, et al. Clinical features and prognosis of children with lymphoblastic lymphoma. Zhonghua Zhong Liu Za Zhi. 2012;34(2):138–42.
Kobayashi R, et al. Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols. Int J Hematol. 2014;99(6):743–9.
Sun XF, et al. Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma. Int J Clin Oncol. 2008;13(5):436–41.
Gao YJ, et al. Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010. Pediatr Blood Cancer. 2014;61(4):659–63.
Sunami S, et al. Prognostic impact of intensified maintenance therapy on children with advanced lymphoblastic lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 study. Pediatr Blood Cancer. 2016;63(3):451–7.
Termuhlen AM, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children’s Oncology Group. Br J Haematol. 2013;162(6):792–801.
Sterba J, et al. Capizzi methotrexate with BFM backbone without craniospinal irradiation is effective treatment for pediatric lymphoblastic lymphoma: results from 5 countries with I-BFM LL 09 protocol. Br J Haematol. 2015;171(Suppl.1):33.
Mitsui T, et al. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer. 2009;52(5):591–5.
Gross TG, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2009;16(2):223–30.
Burkhardt B, et al. Outcome of adolescents with Non-Hodgkin Lymphoma in the BFM studies: Relevance of gender and histological subtype. In: 3rd International Symposium on Childhood, adolescent and young adult Non-Hodgkin’s Lymphoma. Frankfurt, Germany: Hematology meeting reports; 2009.
Cohen MH, et al. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist. 2008;13(6):709–14.
Dunsmore KP, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(22):2753–9.
Winter SS, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015;62(7):1176–83.
Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):580–8.
Pileri SA, et al. Anaplastic large cell lymphoma: update of findings. Leuk Lymphoma. 1995;18(1–2):17–25.
Stansfeld AG, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1(8580):292–3.
Harris NL, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.
Morris SW, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4.
Delsol G, Jaffe ES, Falini B, Gascoyne RD, Muller-Hermelink HK, Stein H, Campo E, Kinney MC. Anaplastic Large Cell Lymphoma (ALCL), ALK-positive. In: Swerdlow S, Campo E, Harris NL, editors. WHO classification of tumors of the hematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC; 2008. p. 312–6.
Oschlies I, et al. ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica. 2013;98(1):50–6.
Swerdlow SH, Webber SA, Chadburn A. Post-Transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Lee Harris N, editors. WHO classification of tumors of the hematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer (IARC); 2008. p. 343–51.
Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34(9):963–71.
Mussolin L, et al. Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma. Leukemia. 2005;19(9):1643–7.
Grewal JS, et al. Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol. 2007;86(7):499–508.
Kinney MC, et al. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol. 1993;17(9):859–68.
Bayle C, et al. Leukaemic presentation of small cell variant anaplastic large cell lymphoma: report of four cases. Br J Haematol. 1999;104(4):680–8.
Onciu M, et al. ALK-positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis. Report of three cases and review of the literature. Am J Clin Pathol. 2003;120(4):617–25.
Spiegel A, et al. Paediatric anaplastic large cell lymphoma with leukaemic presentation in children: a report of nine French cases. Br J Haematol. 2014;165(4):545–51.
Malcolm TI, et al. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. Nat Commun. 2016;7:10087.
Turner SD, et al. Anaplastic large cell lymphoma in paediatric and young adult patients. Br J Haematol. 2016;173(4):560–72.
Iwahara T, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439–49.
Borer RA, et al. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56(3):379–90.
Perkins SL, et al. Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol. 2005;131(5):624–7.
Stein H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–95.
Zhang Q, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168(1):466–74.
Kasprzycka M, et al. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A. 2006;103(26):9964–9.
Marzec M, et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007;26(38):5606–14.
Marzec M, et al. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene. 2007;26(6):813–21.
Nieborowska-Skorska M, et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res. 2001;61(17):6517–23.
Slupianek A, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 2001;61(5):2194–9.
Marzec M, et al. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming. J Immunol. 2013;191(12):6200–7.
Werner MT, et al. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Blood. 2017;129(7):823–31.
Crescenzo R, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516–32.
Marzec M, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008;105(52):20852–7.
Zhang Q, et al. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Proc Natl Acad Sci U S A. 2011;108(29):11977–82.
Krenacs L, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin’s disease: evidence for distinct cellular origin. Blood. 1997;89(3):980–9.
Foss HD, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996;88(10):4005–11.
Matsuyama H, et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood. 2011;118(26):6881–92.
Laurent C, et al. Circulating t(2;5)-positive cells can be detected in cord blood of healthy newborns. Leukemia. 2012;26(1):188–90.
Moti N, et al. Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene. 2015;34(14):1843–52.
Brugieres L, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897–903.
Williams DM, et al. Anaplastic large cell lymphoma in childhood: analysis of 72 patients treated on The United Kingdom Children’s Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117(4):812–20.
Brugieres L, et al. CD30(+) anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591–8.
Seidemann K, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699–706.
Rosolen A, et al. Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Cancer. 2005;104(10):2133–40.
Lowe EJ, et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children’s Cancer Group Study 5941. Pediatr Blood Cancer. 2009;52(3):335–9.
Brugieres L, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27(30):5056–61.
Woessmann W, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065–71.
Brugieres L, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol. 2000;11(1):53–8.
Strullu M, et al. Hematopoietic stem cell transplantation in relapsed ALK+ anaplastic large cell lymphoma in children and adolescents: a study on behalf of the SFCE and SFGM-TC. Bone Marrow Transplant. 2015;50(6):795–801.
Laver JH, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541–7.
Alexander S, et al. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children’s oncology group. Pediatr Blood Cancer. 2014;61(12):2236–42.
Le Deley MC, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28(25):3987–93.
Le Deley MC, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111(3):1560–6.
Lamant L, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669–76.
Damm-Welk C, et al. Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2007;110(2):670–7.
Damm-Welk C, et al. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction. Br J Haematol. 2007;138(4):459–66.
Mussolin L, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27(2):416–22.
Ait-Tahar K, et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood. 2010;115(16):3314–9.
Mori T, et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol. 2006;132(5):594–7.
Woessmann W, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents—a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133(2):176–82.
Ruf S, et al. Risk-adapted therapy for patients with relapsed or refractory ALCL—Final Report of the Prospective ALCL-Relapse Trial of the EICNHL. In: Fifth International Symposium on Childhood Adolescent and Young Adult Non-Hodgkin Lymphoma. Varese, Italy: British Journal of Haematology; 2015. p. 45.
Shaw AT, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94.
Li J, et al. Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs. J Mol Model. 2016;22(9):231.
Mosse YP, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–80.
Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254–62.
Wang Y, et al. Structural insights into the pharmacophore of vinca domain inhibitors of microtubules. Mol Pharmacol. 2016;89(2):233–42.
Pro B, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.
Younes A, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–56.
Cole PD, et al. Phase 2 trial of brentuximab vedotin and gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin Lymphoma (HL): a Children’s Oncology Group (COG) report. J Clin Oncol. 2017;35:7527.
Flerlage JE, et al. Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma. Cancer Chemother Pharmacol. 2016;78(6):1217–23.
Mikles B, et al. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma. J Pediatr Hematol Oncol. 2014;36(2):e85–7.
Koh KN, et al. Successful use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical stem cell transplantation and maintenance therapy post-transplantation. Pediatr Blood Cancer. 2015;62(6):1063–5.
Fanale M, et al. Complete Remissions Observed in a Subset of Pediatric Patients with CD30-expressing Malignant Lymphomas Treated in Clinical Studies of Brentuximab Vedotin (SGN-35). In: European Multidisciplinary Cancer Congress; 2011; Stockholm, Sweden. p. S640.
Laimer D, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nat Med. 2012;18(11):1699–704.
Tanaka H, et al. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009;69(17):6987–94.
Singh VK, et al. Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma. Clin Exp Immunol. 2016;186(1):96–105.
Ait-Tahar K, et al. B and CTL responses to the ALK protein in patients with ALK-positive ALCL. Int J Cancer. 2006;118(3):688–95.
Chiarle R, et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008;14(6):676–80.
Thomas L. On immunosurveillance in human cancer. Yale J Biol Med. 1982;55(3–4):329–33.
Burnet FM. Immunological surveillance in neoplasia. Transplant Rev. 1971;7:3–25.
Vajdic CM, et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood. 2010;116(8):1228–34.
Shapiro RS. Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am J Hematol. 2011;86(1):48–55.
Hayashi RJ, Wistinghausen B, Shiramazu B. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Wolters Kluwers; 2016. p. 604–16.
Gross TG, Termuhlen AM. Pediatric non-Hodgkin lymphoma. Curr Hematol Malig Rep. 2008;3(3):167–73.
Styczynski J, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57(6):794–802.
Barker JN, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant. 2001;7(7):395–9.
Brunstein CG, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007;110(8):3064–70.
Dumas PY, et al. Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Societe Francaise de Greffe de Moelle-Therapie Cellulaire collaborative study. Bone Marrow Transplant. 2013;48(2):253–6.
Wistinghausen B, Gross TG, Bollard C. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Pediatr Hematol Oncol. 2013;30(6):520–31.
Baker KS, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21(7):1352–8.
Sanz J, Andreu R. Epstein-Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation. Curr Opin Oncol. 2014;26(6):677–83.
Collins MH, et al. Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. Pediatrics. 2001;107(6):E89.
Gross TG, Savoldo B, Punnett A. Posttransplant lymphoproliferative diseases. Pediatr Clin N Am. 2010;57(2):481–503, table of contents.
Matthews K, et al. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients. Pediatr Transplant. 2010;14(3):402–8.
Gibelli NE, et al. Sirolimus in pediatric liver transplantation: a single-center experience. Transplant Proc. 2009;41(3):901–3.
Weintraub L, et al. Identifying predictive factors for posttransplant lymphoproliferative disease in pediatric solid organ transplant recipients with Epstein-Barr virus viremia. J Pediatr Hematol Oncol. 2014;36(8):e481–6.
Allen UD. The ABC of Epstein-Barr virus infections. Adv Exp Med Biol. 2005;568:25–39.
San-Juan R, et al. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):109–18.
Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol. 2001;39(4):1211–6.
Savoldo B, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005;5(3):566–72.
Kanakry JA, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127(16):2007–17.
Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol. 1997;14(1):8–14.
Miloh T, et al. T-cell PTLD presenting as acalculous cholecystitis. Pediatr Transplant. 2008;12(6):717–20.
Gross TG, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children’s Oncology Group Report. Am J Transplant. 2012;12(11):3069–75.
Gulley ML, et al. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation. 2003;76(6):959–64.
Ranganathan S, Jaffe R. Is there a difference between Hodgkin’s disease and a Hodgkin’s-like post-transplant lymphoproliferative disorder, and why should that be of any interest? Pediatr Transplant. 2004;8(1):6–8.
Capello D, Gaidano G. Post-transplant lymphoproliferative disorders: role of viral infection, genetic lesions and antigen stimulation in the pathogenesis of the disease. Mediterr J Hematol Infect Dis. 2009;1(2):e2009018.
Morscio J, et al. Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant. 2013;13(5):1305–16.
Allen U, et al. Gene expression using microarrays in transplant recipients at risk of EBV lymphoproliferation after organ transplantation: preliminary proof-of-concept. Pediatr Transplant. 2009;13(8):990–8.
Styczynski J, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43(10):757–70.
Humar A, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation. 2006;81(6):856–61.
Ghosh SK, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012;119(4):1008–17.
Perrine SP, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571–8.
Hayashi RJ, et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23(1):14–8.
Gross TG, et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23(27):6481–8.
Webber SA, Harmon W, Faro A, Green M, Sarwal M, Hayashi R, Canter C, Thomas D, Jaffe R, Fine R. Anti-CD20 Monoclonal Antibody (rituximab) for Refractory PTLD after Pediatric Solid Organ Transplantation: Multicenter Experience from a Registry and from a Prospective Clinical Trial. In: American Society of Hematology Annual Meeting; 2004. p. Abstract 746.
Maecker-Kohlhoff B, Beier R, Zimmermann M, Schlegelberger B, Baumann U, Mueller CM, Pape L, Reiter A, Rossig C, Schubert S, Toenshoff B, Wingen A, Meissner B, Kebelmann-Betzing C, Henze G, Kreipe HH, Klein C. Response-adapted sequential immuno-chemotherapy of post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients: results from the prospective ped-PTLD 2005 trial. In: Loewenberg B, editor. American Society of Hematology. San Francisco, CA: The American Society of Hematology; 2014. p. 4468.
van Esser JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364–9.
Styczynski J, et al. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11(5):383–92.
Choquet S, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood. 2006;107(8):3053–7.
Papadopoulos EB, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185–91.
Bollard CM, Rooney CM, Heslop HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012;9(9):510–9.
O’Reilly RJ, et al. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195–216.
Bollard CM, et al. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011;13(5):518–22.
Haque T, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123–31.
Doubrovina E, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood. 2012;119(11):2644–56.
Leen AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–23.
Anurathapan U, et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014;22(3):623–33.
Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016;127(26):3331–40.
Vickers MA, et al. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease. Br J Haematol. 2014;167(3):402–10.
Heslop HE, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–35.
Naik S, et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016;137(5):1498–1505 e1.
O’Reilly RJ, et al. Virus-specific T-cell banks for ‘off the shelf’ adoptive therapy of refractory infections. Bone Marrow Transplant. 2016;51(9):1163–72.
Dharnidharka VR, Mohanakumar T. New approaches to treating B-cell cancers induced by Epstein-Barr virus. N Engl J Med. 2015;372(6):569–71.
Ricciardelli I, et al. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood. 2014;124(16):2514–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wistinghausen, B., Burkhardt, B. (2019). Aggressive Lymphoma in Children and Adolescents. In: Lenz, G., Salles, G. (eds) Aggressive Lymphomas. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-00362-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-030-00362-3_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-00361-6
Online ISBN: 978-3-030-00362-3
eBook Packages: MedicineMedicine (R0)